161 related articles for article (PubMed ID: 28551101)
21. Distinct and overlapping binding sites for IKP104 and vinblastine on tubulin.
Chaudhuri AR; Tomita I; Mizuhashi F; Murata K; Ludueña RF
J Protein Chem; 1998 Oct; 17(7):685-90. PubMed ID: 9853684
[TBL] [Abstract][Full Text] [Related]
22. Structure-activity analysis of the interaction of curacin A, the potent colchicine site antimitotic agent, with tubulin and effects of analogs on the growth of MCF-7 breast cancer cells.
Verdier-Pinard P; Lai JY; Yoo HD; Yu J; Marquez B; Nagle DG; Nambu M; White JD; Falck JR; Gerwick WH; Day BW; Hamel E
Mol Pharmacol; 1998 Jan; 53(1):62-76. PubMed ID: 9443933
[TBL] [Abstract][Full Text] [Related]
23. Total synthesis of a key series of vinblastines modified at C4 that define the importance and surprising trends in activity.
Yang S; Sankar K; Skepper CK; Barker TJ; Lukesh JC; Brody DM; Brütsch MM; Boger DL
Chem Sci; 2017 Feb; 8(2):1560-1569. PubMed ID: 28194270
[TBL] [Abstract][Full Text] [Related]
24. Total synthesis and evaluation of vinblastine analogues containing systematic deep-seated modifications in the vindoline subunit ring system: core redesign.
Schleicher KD; Sasaki Y; Tam A; Kato D; Duncan KK; Boger DL
J Med Chem; 2013 Jan; 56(2):483-95. PubMed ID: 23252481
[TBL] [Abstract][Full Text] [Related]
25. Synthesis and structure-activity relationship studies of cytotoxic ester and ether anhydrovinblastine derivatives.
Zhang HK; Shao Y; Ding H; Hu LH
J Nat Prod; 2008 Oct; 71(10):1669-76. PubMed ID: 18771244
[TBL] [Abstract][Full Text] [Related]
26. Rational design of biaryl pharmacophore inserted noscapine derivatives as potent tubulin binding anticancer agents.
Santoshi S; Manchukonda NK; Suri C; Sharma M; Sridhar B; Joseph S; Lopus M; Kantevari S; Baitharu I; Naik PK
J Comput Aided Mol Des; 2015 Mar; 29(3):249-70. PubMed ID: 25481458
[TBL] [Abstract][Full Text] [Related]
27. Syntheses of 5a'-homo-vinblastine and congeners designed to establish structural determinants for isolation of atropisomers.
Kuehne ME; Cowen SD; Xu F; Borman LS
J Org Chem; 2001 Aug; 66(16):5303-16. PubMed ID: 11485449
[TBL] [Abstract][Full Text] [Related]
28. Localization of the vinblastine-binding site on beta-tubulin.
Rai SS; Wolff J
J Biol Chem; 1996 Jun; 271(25):14707-11. PubMed ID: 8663038
[TBL] [Abstract][Full Text] [Related]
29. Modulation of drug cytotoxicity in wild-type and multidrug-resistant tumor cells by stereoisomeric series of C-20'-vinblastine congeners that lack antimicrotubule activity.
Borman LS; Bornmann WG; Kuehne ME
Cancer Chemother Pharmacol; 1993; 31(5):343-9. PubMed ID: 8431967
[TBL] [Abstract][Full Text] [Related]
30. Interaction of vinca alkaloids with tubulin: a comparison of vinblastine, vincristine, and vinorelbine.
Lobert S; Vulevic B; Correia JJ
Biochemistry; 1996 May; 35(21):6806-14. PubMed ID: 8639632
[TBL] [Abstract][Full Text] [Related]
31. Mechanism of action cryptophycin. Interaction with the Vinca alkaloid domain of tubulin.
Smith CD; Zhang X
J Biol Chem; 1996 Mar; 271(11):6192-8. PubMed ID: 8626409
[TBL] [Abstract][Full Text] [Related]
32. Indirubin, a bis-indole alkaloid binds to tubulin and exhibits antimitotic activity against HeLa cells in synergism with vinblastine.
Mohan L; Raghav D; Ashraf SM; Sebastian J; Rathinasamy K
Biomed Pharmacother; 2018 Sep; 105():506-517. PubMed ID: 29883946
[TBL] [Abstract][Full Text] [Related]
33. Asymmetric total synthesis of vindorosine, vindoline, and key vinblastine analogues.
Sasaki Y; Kato D; Boger DL
J Am Chem Soc; 2010 Sep; 132(38):13533-44. PubMed ID: 20809620
[TBL] [Abstract][Full Text] [Related]
34. Molecular modelling studies on Arylthioindoles as potent inhibitors of tubulin polymerization.
Coluccia A; Sabbadin D; Brancale A
Eur J Med Chem; 2011 Aug; 46(8):3519-25. PubMed ID: 21621885
[TBL] [Abstract][Full Text] [Related]
35. Biochemical characterization and molecular dynamic simulation of β-sitosterol as a tubulin-binding anticancer agent.
Mahaddalkar T; Suri C; Naik PK; Lopus M
Eur J Pharmacol; 2015 Aug; 760():154-62. PubMed ID: 25912799
[TBL] [Abstract][Full Text] [Related]
36. Total synthesis of vinblastine, related natural products, and key analogues and development of inspired methodology suitable for the systematic study of their structure-function properties.
Sears JE; Boger DL
Acc Chem Res; 2015 Mar; 48(3):653-62. PubMed ID: 25586069
[TBL] [Abstract][Full Text] [Related]
37. Dissociation of tubulin assembly-inhibiting and aggregation-promoting activities by a vinblastine derivative.
Rai SS; Wolff J
FEBS Lett; 1997 Oct; 416(3):251-3. PubMed ID: 9373163
[TBL] [Abstract][Full Text] [Related]
38. Dolastatin 15, a potent antimitotic depsipeptide derived from Dolabella auricularia. Interaction with tubulin and effects of cellular microtubules.
Bai R; Friedman SJ; Pettit GR; Hamel E
Biochem Pharmacol; 1992 Jun; 43(12):2637-45. PubMed ID: 1632820
[TBL] [Abstract][Full Text] [Related]
39. [Recent results in the field of vinblastine group antitumour alkaloids. Biochemical studies].
Potier P; Guénard D; Zavala F
C R Seances Soc Biol Fil; 1979; 173(2):414-24. PubMed ID: 159763
[TBL] [Abstract][Full Text] [Related]
40. Antitumor agents. 139. Synthesis and biological evaluation of thiocolchicine analogs 5,6-dihydro-6(S)-(acyloxy)- and 5,6-dihydro-6(S)-[(aroyloxy)methyl]-1,2,3-trimethoxy-9-(methylthio)-8H- cyclohepta[a]naphthalen-8-ones as novel cytotoxic and antimitotic agents.
Sun L; McPhail AT; Hamel E; Lin CM; Hastie SB; Chang JJ; Lee KH
J Med Chem; 1993 Mar; 36(5):544-51. PubMed ID: 8496935
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
